Publications by authors named "Tarek Mekhail"

84Publications

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

N Engl J Med 2018 12 25;379(24):2342-2350. Epub 2018 Sep 25.

From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), Florida Cancer Specialists, Fleming Island (A.V.), and Florida Hospital Cancer Institute, Orlando (T.M.) - all in Florida; Tennessee Oncology, Chattanooga (D.D.), and Sarah Cannon Research Institute, Nashville (D.D., D.R.S.) - both in Tennessee; Hospital Universitario Virgen Macarena, Seville (D.V.), and Hospital Universitario 12 de Octubre, CiberOnc, Universidad Complutense and Spanish National Cancer Research Center (L.P.-A.), and Hospital Universitario La Paz (J.C.C.), Madrid - all in Spain; Kanagawa Cancer Center, Yokohama (S.M.), Kansai Medical University Hospital, Hirakata (T.K.), Kurume University Hospital, Kurume (T.T.), and Nippon Medical School Hospital, Tokyo (K.K.) - all in Japan; Westmead Hospital and the University of Sydney, Sydney (R.H.), and Flinders University and Flinders Medical Centre, Adelaide, SA (C.S.K.) - all in Australia; Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju (K.H.L.), Yonsei Cancer Center, Yonsei University College of Medicine, Seoul (B.C.C.), and Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju (Y.-C.K.) - all in South Korea; Vivantes Klinikum Neukoelln, Berlin (M.W.), and the Lung Clinic, Airway Research Center North, German Center for Lung Research, Grosshansdorf (M.R.) - both in Germany; Centre Hospitalier Universitaire de Liège, Liège (M.B.), and University Hospitals KU Leuven, Leuven (J.V.) - both in Belgium; Centre Hospitalier Universitaire de Montpellier and Institut du Cancer de Montpellier Val d'Aurelle, Montpellier (X.Q.), Institut Gustave Roussy, Villejuif (D.P.), and Institut de Cancérologie de l'Ouest-site René Gauducheau, Saint Herblain (S.H.) - all in France; National Koranyi Institute of Pulmonology, Budapest, Hungary (G.O.); the University of Manchester and the Christie NHS Foundation Trust, Manchester (C.F.-F.), AstraZeneca, Alderley Park (C.W.), and AstraZeneca, Cambridge (M.T.) - all in the United Kingdom; AstraZeneca, Gaithersburg, MD (G.M., P.A.D.); and Istanbul University-Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey (M.Ö.).

View Article and Find Full Text PDF
December 2018

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.

J Clin Oncol 2018 08 16;36(22):2251-2258. Epub 2018 May 16.

Benjamin J. Solomon, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Dong-Wan Kim, Seoul National University Hospital, Seoul, Republic of Korea; Yi-Long Wu, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou; Tony S. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; Kazuhiko Nakagawa, Kindai University Faculty of Medicine, Osaka, Japan; Tarek Mekhail, Florida Hospital, Orlando, FL; Enriqueta Felip, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain; Federico Cappuzzo, Azienda Unità Sanitaria Locale Della Romagna, Ravenna; Jolanda Paolini and Tiziana Usari, Pfizer Oncology, Milan, Italy; Yiyun Tang and Keith D. Wilner, Pfizer Oncology, La Jolla, CA; and Fiona Blackhall, Manchester University, and Christie Hospital National Health Service Foundation Trust, Manchester, United Kingdom.

View Article and Find Full Text PDF
August 2018

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

N Engl J Med 2017 11 8;377(20):1919-1929. Epub 2017 Sep 8.

From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and Florida Hospital Cancer Institute, Orlando (T.M.) - all in Florida; Tennessee Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville - both in Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de Cáncer, Universidad Complutense and the Spanish National Cancer Research Center (L.P.-A.), and Hospital Universitario La Paz (J.C.C.), Madrid - all in Spain; Kanagawa Cancer Center, Yokohama (S.M.), Kansai Medical University Hospital, Hirakata (T.Y.), Kurume University Hospital, Kurume (T.T.), and Nippon Medical School Hospital, Tokyo (K.K.) - all in Japan; Westmead Hospital and the University of Sydney, Sydney (R.H.), and Flinders University and Flinders Medical Centre, Bedford Park, SA (C.S.K.) - all in Australia; Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju (K.H.L.), Yonsei Cancer Center, Yonsei University College of Medicine, Seoul (B.C.C.), and Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju (Y.-C.K.) - all in South Korea; Vivantes Klinikum Neukölln, Berlin (M.W.); Centre Hospitalier Universitaire de Liège, Liège, Belgium (M.B.); Centre Hospitalier Universitaire Montpellier and Cancer Institute of Montpellier Val d'Aurelle, Montpellier (X.Q.), Institut Gustave Roussy, Villejuif (D.P.), and Institut de Cancérologie de l'Ouest-Site René Gauducheau, Saint Herblain (S.H.) - all in France; National Koranyi Institute of Pulmonology, Budapest, Hungary (G.O.); AstraZeneca, Alderley Park, United Kingdom (C.W.); AstraZeneca, Gaithersburg, MD (G.M., H.J., Y.H., P.A.D.); and Istanbul University Cerrahpasa School of Medicine, Istanbul, Turkey (M.Ö.).

View Article and Find Full Text PDF
November 2017

Programmed Death Ligand-1 (PD-L1) Expression in the Programmed Death Receptor-1 (PD-1)/PD-L1 Blockade: A Key Player Against Various Cancers.

Arch Pathol Lab Med 2017 Jun 18;141(6):851-861. Epub 2017 Apr 18.

From the Departments of Internal Medicine (Drs Guan, Lim, and Mekhail) and Pathology and Laboratory Medicine (Dr Chang), Florida Hospital, Orlando; and the Department of Pathology, University of Central Florida College of Medicine, Orlando (Dr Chang).

View Article and Find Full Text PDF
June 2017

Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.

J Clin Oncol 2016 08 28;34(24):2858-65. Epub 2016 Mar 28.

Benjamin J. Solomon, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Federico Cappuzzo, Istituto Toscano Tumori, Livorno; Jolanda Paolini, Jennifer Tursi, and Tiziana Usari, Pfizer Oncology, Milan, Italy; Enriqueta Felip, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain; Fiona H. Blackhall, The Christie Hospital and Institute of Cancer Sciences, Manchester University, Manchester, United Kingdom; Daniel B. Costa, Beth Israel Deaconess Center, Boston, MA; Tarek Mekhail, Florida Hospital Cancer Institute, Orlando, FL; Keith D. Wilner and Paulina Selaru, Pfizer Oncology, La Jolla, CA; Dong-Wan Kim, Seoul National University Hospital, Seoul, South Korea; Kazuhiko Nakagawa, Kinki University, Osaka, Japan; Yi-Long Wu, Guangdong Lung Cancer Institute, Guangzhou, China; and Tony S.K. Mok, State Key Laboratory of South China, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Shatin, China.

View Article and Find Full Text PDF
August 2016

Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.

J Clin Oncol 2016 Mar 23;34(7):661-8. Epub 2015 Nov 23.

Sai-Hong Ignatius Ou, University of California Irvine School of Medicine, Orange, CA; Jin Seok Ahn, Sungkyunkwan University School of Medicine; Luigi De Petris, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden; Ramaswamy Govindan, Washington University School of Medicine, St Louis, MO; James Chih-Hsin Yang, National Taiwan University, Taipei, Taiwan; Brett Hughes, The Prince Charles Hospital, Chermside, and University of Queensland, Queensland, Australia; Hervé Lena, Centre Hospitalier Universitaire de Rennes, Rennes; Denis Moro-Sibilot, Centre Hospitalier Universitaire de Grenoble, Institut National de la Santé et de la Recherche Médicale U823, Grenoble, France; Alessandra Bearz, National Cancer Institute, Aviano, Italy; Santiago Viteri Ramirez, Quiron-Dexeus University Hospital, Barcelona, Spain; Tarek Mekhail, Florida Hospital Cancer Institute, Orlando, FL; Alexander Spira, Virginia Cancer Specialists, Fairfax, VA; and Walter Bordogna, Bogdana Balas, Peter N. Morcos, Annabelle Monnet, and Ali Zeaiter, F. Hoffmann-La Roche, Basel, Switzerland; Dong-Wan Kim, Seoul National University Hospital, Seoul, South Korea.

View Article and Find Full Text PDF
March 2016

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

N Engl J Med 2014 Dec;371(23):2167-77

From Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.); State Key Laboratory of South China, Hong Kong Cancer Institute, Department of Clinical Oncology, Chinese University of Hong Kong, Shatin (T. Mok), and Guangdong Lung Cancer Institute, Guangzhou (Y.-L.W.) - both in China; Seoul National University Hospital, Seoul, South Korea (D.-W.K.); Kinki University, Osaka, Japan (K.N.); Florida Hospital Cancer Institute, Orlando (T. Mekhail); Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona (E.F.); Istituto Toscano Tumori, Livorno (F.C.), and Pfizer Oncology, Milan (J.P., T.U., J.T.) - both in Italy; Pfizer Oncology (S.I.) and Pfizer Global Innovative Pharma Business (A.R.) - both in New York; Pfizer Oncology, La Jolla, CA (K.D.W.); and the Christie Hospital and Institute of Cancer Sciences, Manchester University, Manchester, United Kingdom (F.B.).

View Article and Find Full Text PDF
December 2014

Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer.

Invest New Drugs 2014 Apr 15;32(2):362-8. Epub 2014 Jan 15.

University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA,

View Article and Find Full Text PDF
April 2014

The role of consolidation treatment in locally advanced unresectable NSCLC.

Curr Oncol Rep 2013 Aug;15(4):424-32

Internal Medicine Department, Saint Elizabeth Health Center, 1044 Belmont Ave, Youngstown, OH 44501, USA.

View Article and Find Full Text PDF
August 2013

A strong step forward in maintenance therapy for non-small cell lung cancer treatment.

Transl Lung Cancer Res 2012 Jun;1(2):99-101

Florida Hospital Cancer Institute, Orlando, FL, USA.

View Article and Find Full Text PDF
June 2012

Thymic neoplasms: a clinical update.

Curr Oncol Rep 2012 Aug;14(4):350-8

Imperial College London School of Medicine, London, UK.

View Article and Find Full Text PDF
August 2012

Phase-II trial of rebeccamycin analog, a dual topoisomerase-I and -II inhibitor, in relapsed "sensitive" small cell lung cancer.

J Thorac Oncol 2012 Apr;7(4):751-4

Division of Hematology and Oncology, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH, USA.

View Article and Find Full Text PDF
April 2012

Current and emerging medical treatments for non-small cell lung cancer: a primer for pulmonologists.

Respir Med 2012 Apr 25;106(4):473-92. Epub 2011 Nov 25.

Respiratory Institute, Cleveland Clinic, Mail Code A90, 9500 Euclid Avenue, Cleveland, OH 44195, USA.

View Article and Find Full Text PDF
April 2012

Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-α in patients with metastatic renal cell carcinoma.

BJU Int 2012 Jan 18;109(1):63-9. Epub 2011 Jan 18.

Division of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center and Glickman Urological and Kidney Institute, Cleveland, OH 44195, USA.

View Article and Find Full Text PDF
January 2012

Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial.

BJU Int 2011 Feb 14;107(4):562-70. Epub 2010 Sep 14.

Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland Clinic Glickman Urological and Kidney Institute, Cleveland, OH, USA.

View Article and Find Full Text PDF
February 2011

Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression.

Mol Cancer Ther 2010 Aug 3;9(8):2309-21. Epub 2010 Aug 3.

Hematology/Oncology Research, Taussig Cancer Institute, The Cleveland Clinic, 9500 Euclid Avenue/R40, Cleveland, OH 44195, USA.

View Article and Find Full Text PDF
August 2010

Limited resection for early-stage lung cancer.

Curr Oncol Rep 2010 Sep;12(5):285-7

Florida Hospital Cancer Institute, Orlando, FL 32804, USA.

View Article and Find Full Text PDF
September 2010

Small vessel ischemic disease of the brain and brain metastases in lung cancer patients.

PLoS One 2009 Sep 30;4(9):e7242. Epub 2009 Sep 30.

Respiratory Institute, The Cleveland Clinic, Cleveland, Ohio, United States of America.

View Article and Find Full Text PDF
September 2009

A phase I study of sunitinib plus bevacizumab in advanced solid tumors.

Clin Cancer Res 2009 Oct 22;15(19):6277-83. Epub 2009 Sep 22.

Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio 44195, USA.

View Article and Find Full Text PDF
October 2009

Investigational agents in the management of non-small cell lung cancer.

Curr Oncol Rep 2009 Jul;11(4):275-84

Department of Solid Tumor Oncology, Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA.

View Article and Find Full Text PDF
July 2009

Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.

J Clin Oncol 2009 Jan 8;27(2):235-41. Epub 2008 Dec 8.

Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA.

View Article and Find Full Text PDF
January 2009

Phase I/II trial of 5-fluorouracil and a noncytotoxic dose level of suramin in patients with metastatic renal cell carcinoma.

Clin Genitourin Cancer 2008 Sep;6(2):79-85

Division of Hematology and Oncology, Department of Medicine, The University of Texas Health Science Center, San Antonio, TX 78229, USA.

View Article and Find Full Text PDF
September 2008

ProApolipoprotein A1: a serum marker of brain metastases in lung cancer patients.

Cancer 2008 Mar;112(6):1313-24

Cerebrovascular Research, Department of Neurosurgery, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio 44195, USA.

View Article and Find Full Text PDF
March 2008

Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma.

Cancer Chemother Pharmacol 2008 Jul 2;62(2):347-54. Epub 2007 Oct 2.

Experimental Therapeutics Program, Department of Hematology and Medical Oncology/ R33, The Cleveland Clinic Taussig Cancer Center, 9500 Euclid Ave, Cleveland, OH, 44195, USA.

View Article and Find Full Text PDF
July 2008

Lung cancer screening.

Curr Oncol Rep 2007 Jul;9(4):265-74

Department of Pulmonary, Allergy, and Critical Care Medicine, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA.

View Article and Find Full Text PDF
July 2007

Lung cancer screening: is it time for a change in policy?

Cleve Clin J Med 2007 Jun;74(6):441-8

Department of Pulmonary, Allergy, and Critical Care Medicine, Cleveland Clinic, Cleveland, OH 44195, USA.

View Article and Find Full Text PDF
June 2007

Leg weakness in a 66-year-old woman: a common presentation of an uncommon disease.

Cleve Clin J Med 2007 Jan;74(1):23-6, 29-34

Department of Neurology, Cleveland Clinic Foundation, OH 44195, USA.

View Article and Find Full Text PDF
January 2007

Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy.

Lung Cancer 2007 Jun 27;56(3):377-81. Epub 2007 Feb 27.

Division of Hematology/Oncology, Case Western Reserve University and University Hospitals of Cleveland, CASE Comprehensive Cancer Center, Cleveland, Ohio 44106, USA.

View Article and Find Full Text PDF
June 2007

Diagnosis of lung cancer by the analysis of exhaled breath with a colorimetric sensor array.

Thorax 2007 Jul 27;62(7):565-8. Epub 2007 Feb 27.

Department of Pulmonary, Allergy, and Critical Care Medicine, The Cleveland Clinic, 9500 Euclid Avenue, A90 Cleveland, OH 44195, USA.

View Article and Find Full Text PDF
July 2007

Validation of the RTOG recursive partitioning analysis (RPA) classification for small-cell lung cancer-only brain metastases.

Int J Radiat Oncol Biol Phys 2007 Jan 23;67(1):240-3. Epub 2006 Oct 23.

Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.

View Article and Find Full Text PDF
January 2007

Phase 1 trial of Anvirzel in patients with refractory solid tumors.

Invest New Drugs 2006 Sep;24(5):423-7

Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, 9500 Euclid Ave., Cleveland, OH 44195, USA.

View Article and Find Full Text PDF
September 2006

Phase I trial of thalidomide and interleukin-2 in patients with metastatic renal cell carcinoma.

Invest New Drugs 2006 Jul;24(4):321-6

Division of Hematology/Oncology, Department of Internal Medicine, Ohio State University, Columbus, Ohio 43210, USA.

View Article and Find Full Text PDF
July 2006

Phenoxodiol: isoflavone analog with antineoplastic activity.

Curr Oncol Rep 2006 Mar;8(2):104-7

Department of Hematology and Medical Oncology, Taussig Cancer Center, The Cleveland Clinic Foundation, 9500 Euclid Avenue, R-35, Cleveland, OH 44195, USA.

View Article and Find Full Text PDF
March 2006

Malignant acanthosis nigricans, tripe palms and the sign of Leser-Tre'lat, a hint to the diagnosis of early stage ovarian cancer: a case report and review of the literature.

Gynecol Oncol 2006 May 27;101(2):353-5. Epub 2006 Jan 27.

Department of Obstetrics and Gynecology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.

View Article and Find Full Text PDF
May 2006

A woman with headache and blurred vision.

Cleve Clin J Med 2005 Oct;72(10):848, 851

Department of Hematology and Medical Oncology, Taussig Cancer Center, The Cleveland Clinic Foundation, OH 44195, USA.

View Article and Find Full Text PDF
October 2005

Impact of induction concurrent chemoradiotherapy on pulmonary function and postoperative acute respiratory complications in esophageal cancer.

Chest 2005 Jul;128(1):250-5

Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Taussig Cancer Center, R35, 9500 Euclid Ave, Cleveland, OH 44195, USA.

View Article and Find Full Text PDF
July 2005

Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.

J Clin Oncol 2004 Jul;22(14):2891-900

Experimental Therapeutics Program, Department of Hematology and Medical Oncology, Taussig Cancer Center, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA.

View Article and Find Full Text PDF
July 2004

Phase I trial of vinorelbine and diphenylhydantoin in patients with refractory carcinoma.

Invest New Drugs 2004 Aug;22(3):277-84

Experimental Therapeutics Program, Taussig Cancer Center, Cleveland Clinic Foundation.

View Article and Find Full Text PDF
August 2004

Renal cell carcinoma (RCC) and telomerase activity: relationship to stage.

Urol Oncol 2003 Nov-Dec;21(6):424-30

Expermental Therapeutics, Taussig Cancer Center, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA.

View Article and Find Full Text PDF
August 2004

Apoptotic pathways of epothilone BMS 310705.

Gynecol Oncol 2003 Oct;91(1):173-8

The Cleveland Clinic Foundation, Experimental Therapeutics Program, Taussig Cancer Center/R40, 9500 Euclid Avenue, Cleveland, OH 44195, USA.

View Article and Find Full Text PDF
October 2003

An overview of targeted treatments in cancer.

Clin Ther 2003 Aug;25(8):2121-37

Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA.

View Article and Find Full Text PDF
August 2003

Targeted therapy for lung cancer.

Curr Oncol Rep 2003 Jul;5(4):326-33

Taussig Cancer Center, The Cleveland Clinic Foundation, R35, 9500 Euclid Avenue, Cleveland, OH 44195, USA.

View Article and Find Full Text PDF
July 2003

Phase I trial of consensus interferon in patients with metastatic renal cell carcinoma: toxicity and immunological effects.

Clin Cancer Res 2003 Apr;9(4):1354-60

Experimental Therapeutics Program, Cleveland Clinic Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.

View Article and Find Full Text PDF
April 2003

Tubulin interacting agents: novel taxanes and epothilones.

Curr Oncol Rep 2003 Mar;5(2):89-98

Experimental Therapeutics, Taussig Cancer Center, The Cleveland Clinic Foundation, R35, 9500 Euclid Avenue, Cleveland, OH 44195, USA.

View Article and Find Full Text PDF
March 2003

Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies.

Cancer 2003 Jan;97(1):170-8

Experimental Therapeutics Department, Taussig Cancer Center, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA.

View Article and Find Full Text PDF
January 2003

Paclitaxel in cancer therapy.

Expert Opin Pharmacother 2002 Jun;3(6):755-66

Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.

View Article and Find Full Text PDF
June 2002

Acanthosis nigricans with endometrial carcinoma: case report and review of the literature.

Gynecol Oncol 2002 Feb;84(2):332-4

Department of Hematology and Medical Oncology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.

View Article and Find Full Text PDF
February 2002